November 29, 2023 | 1:00 PM - 2:00 PM ET
The analysis of patent protection is an integral part of the development process for cell and gene therapies. In a field where the complexity of patent portfolios and patent claims reflects the complexity of the science, the requirements of 35 U.S.C. § 112 may be critical to defending or challenging the patentability of various aspects of these therapies. Join us as we discuss the state of the law regarding §112, its implications for the types of claims that might apply to cell and gene therapies, and considerations for patent prosecution and challenges in this growing field.